GLP-1 receptor agonists in kidney transplant recipients with pre-existing diabetes: a retrospective cohort study
In a large US registry of diabetic kidney-transplant recipients, those who started a GLP-1 receptor agonist after transplant had roughly half the risk of graft loss and about one-third lower mortality, though randomized confirmation is still needed.
Background
GLP-1 receptor agonists confer cardiovascular, renal, and survival benefits in diabetes, but kidney-transplant recipients differ from trial populations, with longer and more severe diabetes, greater end-organ damage, and higher cardiovascular risk.
Study design
This US retrospective cohort linked a national transplant registry with Medicare claims, including 18,016 first-time kidney-transplant recipients with type 2 diabetes; 10.9% filled at least one post-transplant GLP-1 receptor agonist prescription. Inverse probability of treatment weighting and survival-time matching were used to limit bias.
Key findings
GLP-1 receptor agonist use was associated with a 49% lower incidence of death-censored graft loss (adjusted subhazard ratio 0.51; 95% CI 0.36-0.71) and 31% lower mortality (adjusted hazard ratio 0.69; 95% CI 0.55-0.86), with robust results when matched on survival time.
Clinical implications
These data suggest a meaningful opportunity to improve graft and patient survival in diabetic kidney-transplant recipients, who currently underuse GLP-1 receptor agonists, but randomized trials are needed to confirm causal benefit.
Safety
Safety endpoints were rare and not associated with GLP-1 receptor agonists, except for an increased risk of diabetic retinopathy (adjusted hazard ratio 1.49; 95% CI 1.11-2.00).
Category
Transplant
Source
The Lancet Diabetes & Endocrinology
More from ASNRT News
Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.